C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$6.06 USD
+0.02 (0.33%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $6.04 -0.02 (-0.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.06 USD
+0.02 (0.33%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $6.04 -0.02 (-0.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, C4 Therapeutics, Inc. (CCCC) closed at $6.51, marking a -1.96% move from the previous day.
Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 227.3% upside potential for C4 Therapeutics, Inc. (CCCC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 8.70% and 5.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season
by Zacks Equity Research
C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.